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Background: Carriage of Streptococcus pneumoniae is considered a precursor to pneumococcal diseases including
pneumonia. As part of the Kalgoorlie Otitis Media Research Project, we characterised pneumococci isolated from
the nasopharynx of Western Australian Aboriginal and non-Aboriginal children.
Methods: Between 1999 and 2005, 100 Aboriginal and 180 non-Aboriginal children were followed from birth to
two years, with nasopharyngeal aspirates collected at ages 1–3 and 6–8 weeks, then at 4, 6, 12, 18 and 24 months.
Introduction of 7-valent pneumococcal conjugate vaccine (7vPCV) in 2001 enabled evaluation of its impact on
carriage in study participants according to vaccines doses received. Pneumococcal serotyping was performed by
Quellung and antimicrobial susceptibility by disk diffusion and Etest®. Molecular epidemiology of pneumococcal
isolates was investigated by pulse-field gel electrophoresis and multilocus sequence typing.
Results: Overall, the prevalence of 7vPCV serotypes was similar for Aboriginal and non-Aboriginal children (19 % vs.
16 %), but the prevalence of non-vaccine serotypes was higher in Aboriginal children (22 % vs. 7 %). A multi-resistant 6B
clone (ST90) was found only in non-Aboriginal children. Aboriginal children who received three doses of 7vPCV had
lower odds of carrying 7vPCV serotypes (odds ratio [OR] 0.19, 95 % CI 0.08–0.44) and higher odds of carrying non-
vaccine serotypes (OR 2.37, 95 % CI 1.13–4.99) than unvaccinated Aboriginal children; this finding was not observed in
non-Aboriginal children.
Conclusions: This unique study shows important differences in pneumococcal serotypes, genotypes, and antimicrobial
susceptibility between Aboriginal and non-Aboriginal children living in the same geographic area before widespread
7vPCV use, and highlights the need for ongoing post-vaccination surveillance in outback Australia.
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Pneumonia is a major cause of childhood morbidity and
mortality worldwide and is estimated to be the second
leading cause of death for children under the age of five,
behind preterm birth complications [1]. Although the ma-
jority of disease burden occurs in Africa and south Asia,
indigenous peoples living in high-income countries also
have high rates of pneumonia [2, 3]. Streptococcus pneumo-
niae (the pneumococcus) is the predominant cause of
community-acquired pneumonia [4, 5]. Pneumococci com-
monly reside in the nasopharynx of healthy young children
[6, 7], and there are links between pneumococcal colonisa-
tion and invasive pneumococcal disease, pneumonia, and
otitis media (OM) [8–10]. Studies in Australia have re-
ported higher rates of pneumococcal carriage and disease
in Aboriginal than in non-Aboriginal populations, and
pneumococcal carriage occurs earlier in Aboriginal chil-
dren [11–13]. However, there are no comparative data on
pneumococcal serotypes and antimicrobial susceptibility in
Aboriginal and non-Aboriginal children living in the same
geographic region, either in Australia or elsewhere.
The pneumococcus is a highly diverse species, with vari-
ations in capsule structure giving rise to over 90 known
serotypes. The use of pneumococcal conjugate vaccines
(PCVs) in children can prevent invasive pneumococcal
disease [14, 15] and OM [16, 17] caused by vaccine sero-
types, as well as pneumonia [18, 19]. PCVs also reduce
carriage of vaccine serotypes, but typically this reduction
is associated with increased carriage of non-vaccine sero-
types [6, 7, 20–22]. 7vPCV (which includes serotypes 4,
6B, 9V, 14, 18C, 19F and 23F) was included in the Austra-
lian immunisation schedule in 2001 for Aboriginal and
high risk children, and in 2005 for all other children. This
was replaced by PCV13 (7vPCV + serotypes 1, 3, 5, 6A,
7F, 19A) in 2011 [23].
As part of an investigation into causal pathways to OM,
the Kalgoorlie Otitis Media Research Project examined bac-
terial carriage in young Aboriginal and non-Aboriginal chil-
dren in the Kalgoorlie–Boulder area, Western Australia
[11, 24]. Pneumococcal carriage rates were high in Aborigi-
nal children: 18 % in the first month of life, and ranging be-
tween 51 and 67 % from age 3 months onwards. Equivalent
figures for non-Aboriginal children were 3 % and 26–37 %,
respectively [11]. The number of children in the household
was positively associated with pneumococcal carriage for
both Aboriginal and non-Aboriginal children, and day care
attendance was a risk factor for carriage in non-Aboriginal
children [25]. Here, our aim is to describe the serotypes,
antimicrobial susceptibility, and molecular epidemiology of
pneumococci isolated from the nasopharynx during
the Kalgoorlie Otitis Media Research Project and the
impact of 7vPCV on upper respiratory tract carriage
among participants in this study. We hypothesise that




The design of the Kalgoorlie Otitis Media Research Project
has been described elsewhere [11, 24]. Briefly, between
April 1999 and January 2003, 100 Aboriginal and 180 non-
Aboriginal children residing in the Kalgoorlie–Boulder area
were enrolled soon after birth. Written informed consent
was provided by participants’ guardians. Nasopharyngeal
aspirates (NPAs) were collected at ages 1–3 and 6–8 weeks,
and at 4, 6, 12, 18 and 24 months as previously described
[11]. NPAs were added to 1 ml skim milk-tryptone-
glucose-glycerol broth and placed immediately at −20 ° C
until transfer to −70 ° C within 72 hours. NPAs were col-
lected, rather than nasopharyngeal swabs, to facilitate viral
as well as bacterial detection, and have been shown to have
similar pneumococcal isolation rates to nasopharyngeal
swabs [26]. In July 2001, 7vPCV was introduced into the
routine immunisation schedule for all Australian Aboriginal
children to be given at ages 2, 4 and 6 months with a
catch-up program for all Aboriginal children aged <2 years.
A booster of 23-valent pneumococcal polysaccharide vac-
cine (23vPPV) was recommended for Aboriginal children
at age 18 months. In the absence of a universal 7vPCV pro-
gram for non-Aboriginal children during the study period,
from October 2001 we also offered the same 3-dose sched-
ule of 7vPCV to non-Aboriginal study participants. Vaccin-
ation characteristics of the study population are shown in
Additional file 1: Table S1.
Primary culture and serotyping of pneumococci
Selective media were used to isolate S. pneumoniae [11]
and 4 colonies, preferably morphologically different col-
onies, were subcultured. Serotyping using the Quellung
reaction was performed on all 4 subcultured colonies,
with any identified serotypes reported once per sample
and defined as ‘distinct pneumococcal isolates’.
Antimicrobial susceptibility
Antimicrobial susceptibility testing was performed on one
subcultured pneumococcal isolate from each sample, and
also on any additional serotype or morphologically distinct
isolate identified in the sample. We used disc diffusion
[27] and the minimum inhibitory concentration (MIC) for
penicillin- or ceftriaxone-resistant strains determined by
Etest® (bioMerieux, USA) according to the recommended
breakpoints at the time of testing [28]. Isolates were classi-
fied as penicillin susceptible (MIC ≤ 0.064 μg/ml), penicil-
lin intermediate resistant (MIC > 0.064, ≤ 1.0 μg/ml) or
penicillin resistant (MIC > 1 μg/ml). Isolates were classified
as ceftriaxone susceptible (MIC ≥ 1.0 μg/ml), ceftriaxone
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ant (MIC ≤ 4 μg/ml).
Pulse field gel electrophoresis
Pulse field gel electrophoresis (PFGE) typing was per-
formed as previously described [29] on a subset of 199
pneumococcal isolates that were available for investiga-
tion in May 2003. These isolates were from samples col-
lected between April 1999 and April 2002. Isolates were
from 99 children: 53 non-Aboriginal children contrib-
uted 97 pneumococci and 46 Aboriginal children con-
tributed 102 pneumococci. A single isolate per sample
was typed and the pneumococcal isolates represented a
range of serotypes.
Multilocus sequence typing
To further investigate a multiresistant 6B clone identified
by PFGE, multilocus sequence typing (MLST) was per-
formed on a subset of 6B isolates (n = 12) using a mass
spectrometry based method [30]. Isolates were selected
based upon antimicrobial susceptibility profiles with
approximately half from Aboriginal and half from non-
Aboriginal children. As serotype 19A is commonly as-
sociated with serotype replacement following 7vPCV
introduction [31], twelve 19A isolates from this study
and six 19A isolates collected in Kalgoorlie during 2008
as part of pneumococcal surveillance in Western Aus-
tralian Aboriginal people [32] were also analysed by
MLST.
Data analysis
Statistical analyses were performed using SPSS (version
15.0 for Windows) and the level of statistical significance
was set at p < 0.05. The Mann–Whitney U test was used
to compare the age of Aboriginal and non-Aboriginal
children at vaccination and time from vaccination to
sample collection. Pearson’s chi square was used to test
differences in total vaccine doses received between Abo-
riginal and non-Aboriginal children. The modified Wald
method was used to calculate confidence intervals of
proportions using GraphPad (GraphPad Software Inc,
USA) and the Z test used to compare proportions.
When investigating the effect of vaccination on carriage,
to avoid potential bias related to health-seeking behaviour
(e.g. delayed attendance for immunisation), the cohort was
restricted to include data from those children who never re-
ceived 7vPCV during the study period and those who re-
ceived their first dose of 7vPCV before age 12 months.
Among 7vPCV recipients, only samples collected >14 days
after 7vPCV administration were considered post-vaccine to
allow for the immunologic response to develop. Logistic re-
gression modeling was used to assess the relationship be-
tween 7vPCV vaccination and pneumococcal carriage whilst
adjusting for age. The models incorporated GeneralizedEstimating Equations (GEEs) to account for loss of inde-
pendence due to repeated sampling of individuals. The re-
gression analysis was performed separately for Aboriginal
and non-Aboriginal children. Non-typeable pneumococci
were excluded from this analysis.
Results
A total of 506 nasopharyngeal samples were collected
from Aboriginal children and 1,045 from non-Aboriginal
children. The median number of samples collected was
6 for both Aboriginal and non-Aboriginal children. The
median age at first sample collection was 15 days for
Aboriginal children and 17 days for non-Aboriginal chil-
dren. Information on vaccination status is presented in
Additional file 1: Table S1. The overall pneumococcal
carriage rates (% of samples containing any pneumococ-
cus) were 49.2 % for Aboriginal children and 24.9 % for
non-Aboriginal children, with carriage rates increasing
with age as previously reported [11]. A total of 547 dis-
tinct pneumococcal isolates were identified and subject
to further analysis.
Pneumococcal serotypes
The prevalence (% of samples) of pneumococcal sero-
types (7vPCV serotypes, non-7v PCV13 serotypes, and
non-vaccine types) in study participants is shown in
Fig. 1, with full data available in Additional file 1: Table
S2. Overall, 18.8 % (95 % CI 15.6–22.4) of samples from
Aboriginal children contained 7vPCV serotypes com-
pared to 15.7 % (95 % CI 13.6–18.0) of samples from
non-Aboriginal children. There were no significant dif-
ferences in the prevalence of 7vPCV between Aboriginal
and non-Aboriginal groups when examined in different
age groups (<6 months 17 % vs 10 %, 6 - <12 months
21 % vs 23 %, and ≥12 months 22 % in both). There
were also no differences in prevalence of the most com-
mon serotype, namely 6B, between Aboriginal and non-
Aboriginal children in the 3 age groups (<6 months 3-
4 %, 6- < 12 months 11 %, ≥12 months 8-10 %). Data for
other individual serotypes were too sparse to investigate in
different age groups. For the additional six serotypes con-
tained in 13vPCV, rates were 9.7 % (95 % CI 7.4–12.6)
from Aboriginal children and 2.7 % (95 % CI 1.8–3.9)
from non-Aboriginal children (note that serotype 5 was
not detected in this study). Non-vaccine serotypes were
more common in samples from Aboriginal children
(21.9 % [95 % CI 18.5–25.8]) compared to non-Aboriginal
children (7.1 % [95 % CI 5.7–8.8]), with similar patterns in
different age groups. A broader range of serotypes was
seen in Aboriginal children (33 different serotypes in 506
samples) than in non-Aboriginal children (29 serotypes in
1,045 samples, p = 0.0004). Serotypes 6A, 19A, 16F, 11A,
33F, 9V, and non-typeable pneumococci were more com-
monly found in samples from Aboriginal than non-
Fig. 1 Prevalence (% of samples) of pneumococcal serotypes in carriage samples collected from Aboriginal (solid bars) and non-Aboriginal (hashed bars)
study participants (1999–2005). 7vPCV serotypes are shown in red, with the additional serotypes contained in 13vPCV shown in blue and non-vaccine
types (NVT) shown in grey. NT = non-typeable
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Aboriginal children yielded multiple pneumococcal sero-
types (24 samples with two different serotypes and one
sample with three different serotypes). Twelve (1.1 %)
samples from non-Aboriginal children produced two dif-
ferent serotypes.
Antimicrobial susceptibility
A total of 526 pneumococcal isolates from 507 samples
were tested for susceptibility to penicillin, erythromycin,
tetracycline, cotrimoxazole, chloramphenicol, and ceftriax-
one. Rifampicin and vancomycin susceptibility was tested
for on 478 and 479 isolates, respectively. All isolates were
susceptible to ceftriaxone, rifampicin, and vancomycin.Table 1 Reduced antimicrobial susceptibility of Streptococcus pneum
Aboriginal children
Isolate type Number of
isolates
% with reduced susceptibil
Penicillina Erythrom
7vPCV types
Aboriginal 92 31.5 7.6
Non-Aboriginal 162 35.2 26.5
Non-vaccine types
Aboriginal 151 15.2 4.0
Non-Aboriginal 97 3.1 6.2
Non-typeable
Aboriginal 18 66.7 50.0
Non-Aboriginal 5 60.0 40.0
All pneumococci
Aboriginal 261 24.5 8.4
Non-Aboriginalb 265 23.8 19.2
aPneumococci showed intermediate resistance to penicillin (MIC 0.065-1.0 μg/mL) e
bIncludes 1 isolate not serotypedResults for other antimicrobials are summarised in Table 1,
with detailed results by serotype shown in Additional file 1:
Tables S3 and S4. Overall, 127 (24.1 %) isolates showed re-
duced susceptibility to penicillin, 73 (13.9 %) to erythro-
mycin, 78 (14.8 %) to tetracycline and 147 (27.9 %) to
cotrimoxazole. There were differences in antimicrobial sus-
ceptibility between pneumococci isolated from Aboriginal
and non-Aboriginal children. All isolates from Aboriginal
children were susceptible to chloramphenicol, whereas
13.2 % of isolates from non-Aboriginal children displayed
reduced susceptibility. Reduced penicillin susceptibility of
serotypes 19F and 19A was more common and that of
serotype 6B less common in Aboriginal than in non-
Aboriginal children (19F: 70 % vs. 39 %; 19A 64 % vs. 18 %;oniae in nasopharyngeal samples from Aboriginal and non-
ity to antimicrobial agent









xcept for 1 serotype 23F isolate that showed MIC =1.5 μg/mL
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almost half of the serotype 6B isolates from Aboriginal chil-
dren and 74 % of those from non-Aboriginal children. Of
note, 65 % of non-typeable pneumococci isolated from
Aboriginal and non-Aboriginal children had reduced sus-
ceptibility to penicillin and 74 % had reduced susceptibility
to cotrimoxazole. Overall, 5 % of 503 serotypeable
pneumococci were resistant to two antimicrobials and a
further 9 % to three antimicrobials. Equivalent figures for
23 non-typeable pneumococci were 30 % and 43 %,
respectively.
There were 33 isolates (serotypes 6B, n = 27; 23F, n = 5;
19F, n = 1) from 20 non-Aboriginal children, which
showed reduced susceptibility to penicillin, tetracycline,
erythromycin, cotrimoxazole and chloramphenicol (6.3 %
of all isolates, 12.5 % of isolates from non-Aboriginal chil-
dren). This multi-resistance pattern was not seen in any
isolates from Aboriginal children.Molecular epidemiology
Using PFGE, 67 different molecular types of S. pneumo-
niae were identified among the 199 isolates examined
(Additional file 1: Table S5). Of these, 30 were repre-
sented once and 14 types were seen five or more times.
All 7vPCV serotypes in this population were quite vari-
able except 18C. Only one molecular type (72) wasTable 2 Genotypes and antimicrobial resistance of select 6B and 19
Isolates (n) Ethnicity Serotype Ant
1 Aboriginal 6B cot
1 Aboriginal 6B tetr
4 Aboriginal (3), non-Aboriginal (1) 6B cot
1 Aboriginal 6B cot
4 Non-Aboriginal 6B mu
1 Non-Aboriginal 6B mu
1 Aboriginal 19A non
1 Aboriginal 19A non
1 Non-Aboriginal 19A non
1 Aboriginal 19A cot
1 Non-Aboriginal 19A cot
2 Aboriginal, non-Aboriginal 19A non
1 Aboriginal 19A non
2 Aboriginal 19A non
1 Non-Aboriginal 19A cot
4 (3 from 2008) Aboriginal 19A cot
3 (from 2008) Aboriginal 19A mu
aI Intermediate, R Resistant, multiresistant resistant to cotrimoxazole, erythromycin, a
bND not determined
cSLV single locus variant, DLV double locus variant
dST first reported in this studyfound in both a vaccine (6B) and a non-vaccine (10A)
serotype; these isolates were not from the same child.
MLST was performed on 12 serotype 6B isolates and
18 serotype 19A isolates (6 of which were collected in
2008) (Table 2). The multiresistant 6B clone identified as
molecular type 58 by PFGE was revealed to be ST90, a
globally distributed clone also known as Spain6B-2. Inter-
estingly, ST90 was only found in non-Aboriginal chil-
dren, whereas ST185, a globally distributed clone known
as S. Africa6B-8 was isolated from both Aboriginal and
non-Aboriginal children.
The 6B isolates clustered into two broad clonal com-
plexes, one related to ST385 and one related to ST90.
These two clonal complexes were evenly distributed
throughout the study period. Most of the 19A isolates
were related to ST199, although one 19A isolate was
ST162, which is mainly associated with serotypes 9V and
19F [33]. Three isolates with distinct PFGE molecular
types were all ST199. The six more recent 19A isolates
examined belonged to ST202 and ST320. No serotype
6B isolates were identified in 2008 following widespread
use of 7vPCV.
Pneumococcal carriage and vaccination
A higher proportion of Aboriginal than non-Aboriginal
children received 7vPCV, they were older than non-
Aboriginal children at time of receiving each dose ofA isolates
imicrobial resistancea PFGE typeb Sequence Typec
rimoxazole (I), tetracycline (R) 59 385
acycline (R) ND 385
rimoxazole (R) 60 (2), ND (2) 185 (DLV 385)
rimoxazole (R) ND 4276 (DLV 385)
ltiresistant 58, ND 90




rimoxazole (R) 31 876 (SLV 199)
rimoxazole (R) ND 10264d (DLV 199)
e 18 172
e 34 10262d
e ND 10263d (SLV 10262)
rimoxazole (R) ND 162
rimoxazole (R), tetracycline (R) ND 202
ltiresistant ND 320
nd tetracycline, and chloramphenicol and/or penicillin
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ing 7vPCV to sample collection between Aboriginal and
non-Aboriginal children (Additional file 1: Table S1).
Table 3 shows pneumococcal carriage in unimmunised
children and according to number of doses among those
who received their first dose of 7vPCV before age
12 months. Serotypes were grouped as 7vPCV and non-
7vPCV types for this analysis as numbers were too small
to analyse individually for most serotypes. Similarly, chil-
dren receiving 1 and 2 doses of 7vPCV were grouped due
to small numbers. There were 415 samples from Aborigi-
nal children and 1,010 samples from non-Aboriginal chil-
dren included in this analysis (82 % and 97 % of all study
samples, respectively). From this cohort of Aboriginal chil-
dren, pneumococci were isolated from 105 (40.9 %) sam-
ples from unvaccinated children, 44 (57.1 %) samples
from those who had received one or two doses of 7vPCV,
and 53 (65.4 %) samples from those who had received 3
doses. Equivalent numbers for the non-Aboriginal chil-
dren were 183 (22.3 %), 33 (37.1 %), and 33 (32.4 %), re-
spectively. Note that the increased pneumococcal carriage
with more doses is related to the increase in carriage
prevalence with age during the first year of life [11].
A higher proportion of samples from Aboriginal chil-
dren had non-7vPCV serotypes after receiving 3 doses of
vaccine (46.9 %, 95 % CI 36.4–57.7 %) compared with
samples from those who were not vaccinated (24.5 %,
95 % CI 19.6–30.1 %), while carriage of 7vPCV serotypes
was lower following 3 doses of vaccine than in unvaccin-
ated children (9.9 % [95 % CI 4.9–18.5 %] vs. 17.9 %
[95 % CI 13.7–23.1 %]). In contrast, similar proportions
of 7vPCV and non-7vPCV pneumococcal serotypes were
found in unvaccinated and fully vaccinated non-Aboriginal
children. After controlling for age and accounting for re-
peated sampling, the odds of isolating 7vPCV pneumococ-
cal serotypes in samples from Aboriginal children were
about five times less after three doses of vaccine than inTable 3 Proportion of samples with 7vPCV or non-7vPCV serotypes
or 3 doses of 7vPCV
Doses
0
Aboriginal Samples (n) 257 (%)a
7vPCV serotypes 46 (17.9)
Non-7vPCV serotypes 63 (24.5)
Non-Aboriginal Samples (n) 819 (%)
7vPCV serotypes 110 (13.4
Non-7vPCV serotypes 72 (8.8)
a% = proportion of samples
Note: To avoid potential bias related to health service utilization, data presented he
dose of 7vPCV before age 12 months. Among 7vPCV recipients, only samples collec
Some nasopharyngeal aspirates included more than one 7vPCV or non-7vPCV serot
were excludedsamples from unvaccinated children, and the odds of iso-
lating non-7vPCV types were 2.5 times greater (Table 4).
Similar results were not seen with samples taken from
non-Aboriginal children. However, non-Aboriginal chil-
dren who received 1–2 doses of 7vPCV had an increased
odds of carrying 7vPCV serotypes.
Discussion
To our knowledge, this is the only study to date comparing
the characteristics of pneumococci isolated from the upper
respiratory tract in indigenous children with those in non-
indigenous children living in the same geographic area, and
notably in an arid zone of Australia, for which there is a
dearth of any carriage data. In addition to higher carriage
rates, the distribution of pneumococcal serotypes was more
diverse, and carriage of non-typeable strains and simultan-
eous carriage of multiple serotypes were more common in
Aboriginal than in non-Aboriginal children.
The serotype distribution and antimicrobial susceptibility
patterns differed between Aboriginal and non-Aboriginal
children. Of note, non-PCV7 serotypes 16F, 19A, 6A, and
33F (known to be replacement serotypes following wide-
spread use of PCVs [34, 35]) were more common in Abori-
ginal than in non-Aboriginal children. These differences
may relate, in part at least, to vaccination status: more
Aboriginal children received three doses of 7vPCV, and
these fully vaccinated children were less likely to carry
7vPCV serotypes (Table 4), providing evidence of vaccine
impact on carriage. However, unvaccinated Aboriginal chil-
dren had higher carriage rates overall and higher carriage
of non-7vPCV serotypes (more serotype diversity) than un-
vaccinated non-Aboriginal children, indicating some base-
line differences in pneumococcal carriage.
Non-Aboriginal children receiving 1 or 2 doses of 7vPCV
had increased odds of carrying 7vPCV serotypes when
compared to those who had had no 7vPCV. This finding
was unexpected and the reasons are unclear. It may relatein Aboriginal and non-Aboriginal children who received 0, 1–2,
Total
1-2 3
77 (%) 81 (%) 415 (%)
16 (20.8) 8 (9.9) 70 (16.9)
27 (35.1) 38 (46.9) 128 (30.8)
89 (%) 102 (%) 1010 (%)
) 24 (27.0) 18 (17.6) 152 (15.0)
11 (12.4) 14 (13.7) 97 (9.6)
re are from children who either never received 7vPCV or received their first
ted >14 days after 7vPCV administration were considered post-vaccine
ypes or both 7vPCV and non-7vPCV serotypes. Non-typeable pneumococci
Table 4 Odds Ratios for carriage of S. pneumoniae serotypes in nasopharyngeal samples by vaccine doses received
Serotype Dose 1/2 ORa (95 % CI) Dose 3 OR (95 % CI)
Aboriginal Non-Aboriginal Aboriginal Non-Aboriginal
7vPCV serotypes 0.90 (0.43, 1.88) 1.93 (1.13, 3.32) 0.19 (0.08, 0.44) 0.83 (0.41, 1.66)
Non-7vPCV serotypes 1.83 (1.04, 3.20) 1.25 (0.57, 2.74) 2.50 (1.17, 5.35) 1.19 (0.65, 2.17)
aOR odds ratio from logistic regression, adjusting for age and age-squared and accounting for repeated sampling of individuals, with unvaccinated as the reference category.
Non-typeable pneumococci were excluded
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sociation between health-seeking behaviour and carriage
(i.e. a small proportion of non-Aboriginal parents chose to
have their children vaccinated and those who were vacci-
nated may have been more sickly and more likely to carry
pneumococci), or the lack of herd effects in this community
as 7vPCV was not included in the national immunization
schedule for non-Aboriginal children during the study
period. But the small number of non-Aboriginal children in
this study who received 7vPCV precludes further analysis.
Generally, reduced susceptibility to antimicrobial agents
was observed more often in S. pneumoniae carried by
non-Aboriginal than Aboriginal children, with all multi-
resistant strains isolated from non-Aboriginal children.
An exception was serotype 19F which was more com-
monly resistant when carried by Aboriginal children. The
antimicrobial prescription frequency was similar in Abori-
ginal and non-Aboriginal children in the study, but there
are no available data on specific antimicrobial agents [36].
The reasons for the differences in susceptibility to anti-
microbial agents are unclear, but may relate to differences
in circulating pneumococcal clonal types between the two
population groups or potential differences in the classes of
antibiotics prescribed.
Carriage of serotype 6B was common in both Aborigi-
nal and non-Aboriginal children, but the multi-resistant
clone ST90 was only observed in non-Aboriginal chil-
dren. A multiple-drug resistant clone of 6B was known to
be circulating in Australia from 1988 to 1997 [37]; how-
ever, no MLST results are available from this time period
so it is not known whether this clone was related to ST90.
Reduced susceptibility to antimicrobials was commonly
observed in non-typeable isolates from both populations,
consistent with reports identifying non-typeable pneumo-
cocci as a major reservoir for antimicrobial resistance
genes [38, 39].
As expected, the widespread use of PCV in more recent
years has altered serotype prevalence in carriage. Surveil-
lance of pneumococcal carriage in Aboriginal people in
Western Australia from 2008 to 2011 found a 7 % preva-
lence in 7vPCV serotypes across varying age groups, with
serotypes 19A, 16F and 6C the most common in children
under five years old [32]. Further shifts in serotype distribu-
tion and a reduction in carriage of 19A have been reported
following the switch to PCV13 in 2011 [40]. MLST analysisof serotype 19A isolates suggests that circulating strains may
have changed following 7vPCV introduction. Only a small
number of isolates was examined, so expanded molecular
epidemiological studies would be needed to investigate
whether selective pressure following PCV introduction
results in clonal expansion, as has been observed in
other settings [41].
Limitations of this study include the fact that anti-
serum to serotype 6C (required to differentiate between
6A and 6C) was not available at the time of sample ana-
lysis, so this serotype would not have been detected. It is
also likely that simultaneous carriage of multiple serotypes
was underestimated [42]. Non-typeable pneumococci
were not subject to genetic analysis, therefore could repre-
sent both isolates not producing capsule and “true” non-
typeable pneumococci that lack capsule synthesis genes.
More sophisticated serotyping methodologies are now
available [43]. Antibiotic susceptibility data were not ex-
amined according to vaccine status, due to small numbers
within each dosing group.
An overall reduction in invasive pneumococcal disease
(IPD) and a reduction in IPD caused by 7vPCV serotypes
have been observed in the post-PCV years in Australia, al-
though IPD due to non-vaccine serotypes has increased
[13, 44]. The switch to PCV13 in 2011 has led to further
reductions in IPD, particularly in children under five years
of age [45]. Although a gap still remains, the disparity in
pneumonia hospitalisations between Australian Aboriginal
and non-Aboriginal children has declined over time, likely
due in part to PCV introduction [46].
Conclusions
This study identified important differences in pneumo-
coccal serotypes, genotypes, and antimicrobial suscepti-
bility between Aboriginal and non-Aboriginal children
living in the same region before widespread 7vPCV use.
Ongoing surveillance of pneumococcal carriage is war-
ranted to monitor potential increases in antimicrobial
resistance and changes in serotype distribution that
could impact on pneumococcal disease and health out-
comes, and to help in the continual development of ef-
fective vaccines. Data reported here provide a useful
baseline comparator, as well as insight into some of
the differences in S. pneumoniae carried by Aboriginal
and non-Aboriginal children in Australia.
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